GOQii, a leading smart preventive healthcare company, has joined forces with Acrannolife Genomics to launch the GrafCare Program, a pioneering initiative designed to enhance post-transplant care for organ recipients in India.
This program integrates genomic diagnostics, artificial intelligence, and continuous health monitoring to identify potential complications early and support long-term recovery. Acrannolife’s Trunome test, a non-invasive blood test, detects early signs of organ rejection or infection, while GOQii’s Smart Vital Device monitors key health parameters such as heart rate, blood pressure, and oxygen levels, enabling real-time health tracking. Additionally, patients benefit from expert guidance provided by nutritionists and counselors to aid their recovery journey.
“GrafCare is not just a healthcare initiative—it’s a lifeline for those who have undergone transplants,” stated Vishal Gondal, Founder & CEO of GOQii.
“Our US-patented Trunome test ensures early and precise detection of organ rejection, helping patients safeguard their transplanted organs,” said Agragesh Ramani, Co-founder of Acrannolife Genomics.
Beyond medical support, the program also extends financial assistance, offering interest-free loans, discounts on immunosuppressants, and complimentary diagnostic tests. Given the large number of transplants conducted in India each year, this initiative leverages AI and genomics to help both patients and healthcare professionals proactively manage potential health risks. Moving forward, there are plans to expand the program to other regions with high transplant volumes.
